HC Wainwright Reiterates “Buy” Rating for BrainsWay (NASDAQ:BWAY)

HC Wainwright reaffirmed their buy rating on shares of BrainsWay (NASDAQ:BWAY) in a report published on Wednesday morning,Benzinga reports. They currently have a $16.00 price target on the stock. HC Wainwright also issued estimates for BrainsWay’s Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.06 EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.08 EPS and FY2026 earnings at $0.24 EPS.

BrainsWay Price Performance

Shares of NASDAQ BWAY opened at $10.21 on Wednesday. The business’s 50 day moving average is $10.26 and its two-hundred day moving average is $9.61. The company has a market cap of $192.22 million, a P/E ratio of 102.11 and a beta of 1.29. BrainsWay has a 12 month low of $4.61 and a 12 month high of $11.79.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Lazard Asset Management LLC bought a new position in BrainsWay in the 4th quarter worth approximately $44,000. JPMorgan Chase & Co. increased its position in BrainsWay by 316.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock worth $136,000 after buying an additional 11,221 shares during the period. Sei Investments Co. bought a new position in BrainsWay in the 4th quarter worth approximately $149,000. Cubist Systematic Strategies LLC increased its position in shares of BrainsWay by 14.6% during the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock valued at $181,000 after purchasing an additional 2,446 shares during the period. Finally, Rhumbline Advisers increased its position in shares of BrainsWay by 10.8% during the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock valued at $207,000 after purchasing an additional 2,144 shares during the period. 30.11% of the stock is owned by institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.